Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
26.11
+0.15 (0.58%)
Aug 12, 2026, 11:01 AM EDT - Market open
Nurix Therapeutics Employees
Nurix Therapeutics had 317 employees as of November 30, 2025. The number of employees increased by 31 or 10.84% compared to the previous year.
Employees
317
Change (1Y)
31
Growth (1Y)
10.84%
Revenue / Employee
$115,981
Profits / Employee
-$1,076,817
Market Cap
2.71B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Nov 30, 2025 | 317 | 31 | 10.84% |
| Nov 30, 2024 | 286 | 2 | 0.70% |
| Nov 30, 2023 | 284 | -13 | -4.38% |
| Nov 30, 2022 | 297 | 55 | 22.73% |
| Nov 30, 2021 | 242 | 107 | 79.26% |
| Nov 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Feb 29, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Ultragenyx Pharmaceutical | 1,371 |
| Iovance Biotherapeutics | 975 |
| AbCellera Biologics | 562 |
| Beam Therapeutics | 522 |
| Viridian Therapeutics | 252 |
| Precigen | 160 |
| Kodiak Sciences | 130 |
NRIX News
- 8 days ago - Nurix earns $10M milestone from Sanofi on STAT6 degrader Phase 1 start - TheFly
- 8 days ago - Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader - GlobeNewsWire
- 8 days ago - Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma - GlobeNewsWire
- 15 days ago - Nurix Therapeutics price target raised to $38 from $36 at Morgan Stanley - TheFly
- 21 days ago - Nurix Therapeutics price target raised to $31 from $23 at UBS - TheFly
- 21 days ago - Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology - GlobeNewsWire
- 4 weeks ago - Nurix Therapeutics price target raised to $34 from $30 at Mizuho - TheFly
- 4 weeks ago - Nurix Therapeutics price target raised to $34 from $32 at Truist - TheFly